Bronconex Acticap

Country: Нови Зеланд

Језик: Енглески

Извор: Medsafe (Medicines Safety Authority)

Активни састојак:

Mometasone furoate 400ug (anhydrous)

Доступно од:

Organon (New Zealand) Limited

INN (Међународно име):

Mometasone furoate 400 µg (anhydrous)

Дозирање:

400 mcg/dose

Фармацеутски облик:

Powder for inhalation

Састав:

Active: Mometasone furoate 400ug (anhydrous) Excipient: Lactose

Јединице у пакету:

Inhaler, metered, DPI, (sample), 14 dose units

Класа:

Prescription

Тип рецептора:

Prescription

Произведен од:

MSD International GmbH (Singapore Branch)

Терапеутске индикације:

Bronconex Acticap is indicated for prophylactic therapy in the management of patients with asthma of all severities, including patients who have been dependent upon either inhaled or systemically administered corticosteroids and non-corticosteroid-dependent patients inadequately controlled on other drug regimens.

Резиме производа:

Package - Contents - Shelf Life: Inhaler, metered, DPI, (sample) - 14 dose units - 18 months from date of manufacture stored at or below 25°C - Inhaler, metered, DPI - 30 dose units - 18 months from date of manufacture stored at or below 25°C - Inhaler, metered, DPI - 60 dose units - 18 months from date of manufacture stored at or below 25°C

Датум одобрења:

2000-12-05